



**University of  
Zurich<sup>UZH</sup>**

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2012

---

## **Parvalbumin: calcium and magnesium buffering in the distal nephron**

Olinger, Eric ; Schwaller, Beat ; Loffing, Johannes ; Gailly, Philippe ; Devuyst, Olivier

**Abstract:** Parvalbumin (PV) is a classical member of the EF-hand protein superfamily that has been described as a Ca(2+) buffer and Ca(2+) transporter/shuttle protein and may also play an additional role in Mg(2+) handling. PV is exclusively expressed in the early part of the distal convoluted tubule in the human and mouse kidneys. Recent studies in Pvalb knockout mice revealed a role of PV in the distal handling of electrolytes: the lack of PV was associated with a mild salt-losing phenotype with secondary aldosteronism, salt craving and stronger bones compared with controls. A link between the Ca(2+)-buffering capacity of PV and the expression of the thiazide-sensitive Na(+)-Cl(-) cotransporter was established, which could be relevant to the regulation of sodium transport in the distal nephron. Variants in the PVALB gene that encodes PV have been described, but their relevance to kidney function has not been established. PV is also considered a reliable marker of chromophobe carcinoma and oncocytoma, two neoplasms deriving from the distal nephron. The putative role of PV in tumour genesis remains to be investigated.

DOI: <https://doi.org/10.1093/ndt/gfs457>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-70614>

Journal Article

Published Version

Originally published at:

Olinger, Eric; Schwaller, Beat; Loffing, Johannes; Gailly, Philippe; Devuyst, Olivier (2012). Parvalbumin: calcium and magnesium buffering in the distal nephron. *Nephrology, Dialysis, Transplantation*, 27(11):3988-3994.

DOI: <https://doi.org/10.1093/ndt/gfs457>

Full Review

## Parvalbumin: calcium and magnesium buffering in the distal nephron

Eric Olinger, Beat Schwaller, Johannes Loffing, Philippe Gailly and Olivier Devuyst

Division of Nephrology and Laboratory of Cell Physiology, UCL Medical School, Brussels, Belgium, Institutes of Physiology and Anatomy, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland and Unit of Anatomy, Department of Medicine, University of Fribourg, Fribourg, Switzerland

Correspondence and offprint requests to: Olivier Devuyst; E-mail: olivier.devuyst@uzh.ch

### Abstract

Parvalbumin (PV) is a classical member of the EF-hand protein superfamily that has been described as a  $\text{Ca}^{2+}$  buffer and  $\text{Ca}^{2+}$  transporter/shuttle protein and may also play an additional role in  $\text{Mg}^{2+}$  handling. PV is exclusively expressed in the early part of the distal convoluted tubule in the human and mouse kidneys. Recent studies in *Pvalb* knockout mice revealed a role of PV in the distal handling of electrolytes: the lack of PV was associated with a mild salt-losing phenotype with secondary aldosteronism, salt craving and stronger bones compared with controls. A link between the  $\text{Ca}^{2+}$ -buffering capacity of PV and the expression of the thiazide-sensitive  $\text{Na}^+\text{--Cl}^-$  cotransporter was established, which could be relevant to the regulation of sodium transport in the distal nephron. Variants in the *PVALB* gene that encodes PV have been described, but their relevance to kidney function has not been established. PV is also considered a reliable marker of chromophobe carcinoma and oncocytoma, two neoplasms deriving from the distal nephron. The putative role of PV in tumour genesis remains to be investigated.

**Keywords:** DCT; Gitelman syndrome; NCC; purinergic signalling

### Properties and distribution of parvalbumin


Parvalbumin (PV) is a small protein (109 amino acids in most species; molecular mass  $\sim 12$  kDa) first isolated from carp muscle in 1973 [1] and belonging to the subfamily of cytosolic  $\text{Ca}^{2+}$  buffers in the superfamily of EF-hand proteins [2]. Proteins of the EF-hand family are characterized by a conserved, helix–loop–helix structural unit, which consists of two  $\alpha$ -helices bridged by a  $\text{Ca}^{2+}$ -chelation loop. These proteins are involved in the regulation of many critical cellular processes including gene transcription, protein phosphorylation, nucleotide metabolism and ion transport [3–5]. Over 200 members of the

$\text{Ca}^{2+}$ -binding EF-hand superfamily have been identified so far in the human genome [2].

PV is characterized by a high affinity for  $\text{Ca}^{2+}$  (dissociation constant  $K_{D,\text{Ca}}$ :  $\sim 5\text{--}10$  nM) and an intermediate affinity for  $\text{Mg}^{2+}$  ( $K_{D,\text{Mg}}$ :  $\sim 30$   $\mu\text{M}$ ). Thus, the two functional metal-binding sites are so-called mixed ( $\text{Ca}^{2+}/\text{Mg}^{2+}$ )-binding sites. These properties and the fact that the intracellular concentration of  $\text{Mg}^{2+}$  [ $(\text{Mg}^{2+})_{\text{cyt}}$ , 0.5–1 mM] exceeds largely that of  $\text{Ca}^{2+}$  [ $(\text{Ca}^{2+})_{\text{cyt}}$ , 50–100 nM] in basal conditions explain why PV-binding sites are (>80%) occupied mainly by  $\text{Mg}^{2+}$  in a resting cell. The remaining sites are either  $\text{Ca}^{2+}$ -bound or metal-free. When a stimulus induces a rise in  $[\text{Ca}^{2+}]_{\text{cyt}}$  levels,  $\text{Mg}^{2+}$  slowly dissociates from the binding sites and is replaced by  $\text{Ca}^{2+}$ . Because of the slow  $\text{Ca}^{2+}$ -binding kinetics under physiological conditions, which mainly results from this prior  $\text{Mg}^{2+}$  dissociation, PV is referred to as a slow-onset  $\text{Ca}^{2+}$  buffer [2]. Binding of two  $\text{Ca}^{2+}$  ions to the  $\text{Ca}^{2+}$ -binding sites induces a rather insignificant conformational change [4]. Hence, PV is mostly considered a pure  $\text{Ca}^{2+}$  buffer, with little or no  $\text{Ca}^{2+}$  sensing and direct regulatory properties [6].

The expression of PV is remarkably restricted to a few cell types in the brain, skeletal and heart muscles, parathyroid glands and kidney [7–9]. In the central nervous system, PV is highly expressed in inhibitory GABAergic interneurons, e.g. in the cortex in chandelier (axo-axonic) and basket cells. These cortical neurons play an important role in controlling pyramidal cell excitability. The absence of PV in these cells is linked to increased drug-induced seizure susceptibility [10]. PV is also expressed in similar types of interneurons in the hippocampus (axo-axonic and basket cells) and cerebellum (stellate and basket cells) [7]. In the cerebellum, PV is additionally expressed in Purkinje cells.

In the kidney, PV is expressed in the epithelial cells lining a subset of tubules in the distal nephron (Figure 1). In the mouse and human kidneys, PV appears to be exclusively expressed in the early part of the distal convoluted tubule (early DCT, or DCT1), where it colocalizes with the thiazide-sensitive apical  $\text{Na}^+\text{--Cl}^-$  cotransporter (NCC).




**Fig. 1.** Structure and distribution of PV in the kidney. (A) Segmentation of the distal nephron, with distribution of specific markers in the early (DCT1) and late (DCT2) parts of the distal convoluted tubule, the CNT and the cortical collecting duct (CCD). PV is exclusively expressed in the DCT1, where it colocalizes with the apical NCC. It is of note that the mediators of  $\text{Ca}^{2+}$  reabsorption are expressed in more distal nephron segments (TRPV5; NCX, sodium-calcium exchanger; PMCA, plasma membrane calcium ATPase; CB, calbindin- $\text{D}_{28\text{K}}$ ). The epithelial  $\text{Na}^+$  channel ENaC and CB are expressed all along distal nephron segments, starting in DCT2. MR, medullary ray; G, glomerulus. Modified from Loffing *et al.* [11]. (B) Immunostaining for PV in the human kidney cortex reveals a diffuse cytosolic localization (green signal), sometimes clustered above the basolateral membrane, in cells that express NCC in the apical membrane (red signal). (C) Solution structure of  $\text{Ca}^{2+}$ -bound human PV. The CD domain (green) and EF domain (yellow/red) bind one  $\text{Ca}^{2+}$  ion each (green spheres) in canonical  $\text{Ca}^{2+}$ -binding loops of 12 amino acids. The helices E and F that gave the name to all EF-hand proteins are marked by letters. Both  $\text{Ca}^{2+}$ -binding loops in PV are of the  $\text{Ca}^{2+}/\text{Mg}^{2+}$ -mixed type. The amino- (N) and carboxy- (C) termini are labelled. The image was generated with PDB ProteinWorkshop 1.50 and is modified from Schwaller *et al.* [2].

The progression between the early and late part of the DCT is characterized by an abrupt transition from PV (early DCT) to calbindin- $\text{D}_{28\text{k}}$  (late DCT, or DCT2). Cells expressing calbindin- $\text{D}_{28\text{k}}$  also express NCC and epithelial  $\text{Na}^+$  channel (ENaC) [11, 12]. In the rat kidney, PV has been located in the thick ascending limb (TAL) of the loop of Henle, late DCT, connecting tubule (CNT) and intercalated cells of the collecting duct [13]. Immunocytochemical analyses revealed that in most tubular cells, PV shows a diffuse cytosolic pattern, with a signal sometimes enhanced along the basolateral membrane [12, 13].

PV is present in fast-contracting and fast-relaxing skeletal muscle fibres (e.g. *extensor digitorum longus* or *tibialis anterior*) [14]. The protein has also been detected in normal and in hyperplastic and adenomatous human parathyroid glands, with the strongest expression in chief cells and water clear cells. Of note, PV colocalizes with the parathyroid hormone (PTH) in the same cell types [8].

### Role of PV in the distal nephron

The distal nephron plays a major role in the reabsorption of  $\text{NaCl}$  and the regulation of the final excretion of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ , under the influence of several hormones, including aldosterone, PTH and  $1,25(\text{OH})_2$ -vitamin  $\text{D}_3$  [15]. Approximately 5% of the filtered load of  $\text{NaCl}$  is reabsorbed in the DCT, involving the thiazide-sensitive NCC on the apical side and the  $\text{Na}^+$ - $\text{K}^+$ -ATPase and the  $\text{ClC-Kb}$  chloride channel on the basolateral side of the cells. The reabsorption of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  in that segment is mediated by a complex interaction of different proteins, involving two specific members of the transient receptor potential (TRP) channel superfamily that have a distinct spatial distribution along the DCT (Figure 2). Approximately 5–10% of filtered  $\text{Mg}^{2+}$  is passively reabsorbed through the apical TRPM6 channel and basolateral active transport systems in the DCT1. Specific intracellular



**Fig. 2.** Transcellular transport of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  in the distal nephron. The segmentation of the DCT is reflected by a selective transport machinery facilitating the reabsorption of  $\text{Mg}^{2+}$  in the proximal part of the DCT (DCT1), whereas the  $\text{Ca}^{2+}$  transport is restricted to the more distal part of the DCT (DCT2) and the CNT (not represented on the figure). Magnesium enters the cells lining the DCT1 through apical TRPM6 channels. The nature of the possible transporter and basolateral extruder protein remains unknown. PV is selectively expressed in the cytosol of these cells and plays a role in regulating the  $\text{Ca}^{2+}$  signalling and the expression of the sodium-chloride cotransporter NCC. The transcellular transport of  $\text{Ca}^{2+}$  is mediated through apical TRPV5 channels in the DCT2 and in the CNT. The  $\text{Ca}^{2+}$  buffer calbindin- $\text{D}_{28\text{K}}$  is carrying  $\text{Ca}^{2+}$  ions to the basolateral membrane, where they are extruded by the plasma membrane  $\text{Ca}^{2+}$  ATPase (PMCA1b) and NCX1.

$\text{Mg}^{2+}$  carriers and basolateral extrusion proteins have not yet been identified. Apical TRPV5 channels (previously named epithelial calcium channel 1, ECAC1) mediate the passive entry of  $\text{Ca}^{2+}$  in the DCT2, before active, basolateral transport via the  $\text{Na}^{+}$ - $\text{Ca}^{2+}$  exchanger 1 (NCX1) and plasma membrane  $\text{Ca}^{2+}$ -ATPase 1b (PMCA 1b). In the DCT, TRPV5 colocalizes with the intracellular  $\text{Ca}^{2+}$  buffer/sensor calbindin- $\text{D}_{28\text{K}}$  [16, 17]. Studies in rabbit CNTs have shown that calbindin- $\text{D}_{28\text{K}}$  could be important to lower  $[\text{Ca}^{2+}]_{\text{cyt}}$  levels in order to maintain the necessary gradient for passive cellular  $\text{Ca}^{2+}$  entry and to facilitate the intracellular  $\text{Ca}^{2+}$  diffusional flux [18]. Of interest, the  $\text{Ca}^{2+}$  buffer calbindin- $\text{D}_{9\text{K}}$  is also expressed in DCT2, but with a more focused expression than CB- $\text{D}_{28\text{K}}$  that extends further into the CNTs and collecting ducts (J. Loffing, personal communication).

In view of the specific expression of PV in DCT1, Belge *et al.* [12] investigated in detail the renal phenotype of knockout mice (KO) for PV. In comparison with wild-type littermates, *Pvalb* KO mice had increased diuresis and kaliuresis at baseline, with secondary aldosteronism and salt craving. As expected, an acute administration of the loop diuretic furosemide, aimed to increase sodium

delivery in the DCT, led to increased diuresis and natriuresis/kaliuresis in both genotypes. However, surprisingly, this treatment did not increase calciuria in *Pvalb* KO mice. Furthermore, *Pvalb* KO mice showed no significant diuretic response to hydrochlorothiazide, but rather an accentuated hypocalciuria. The PV-deficient mice also showed an increased bone mineral density. These functional changes were explained by a strongly decreased expression of NCC at the mRNA and protein levels in the early DCT of *Pvalb* KO kidneys, in the absence of any ultrastructural changes [12]. The *Pvalb* KO mice manifested a decreased lithium clearance, suggesting that a compensatory increase in sodium transport was taking place in the proximal tubule—as it has been reported in the case of long-term treatment with thiazide diuretics targeting NCC [19].

What could be the link between the  $\text{Ca}^{2+}/\text{Mg}^{2+}$ -buffering capacities of PV and the expression of NCC in the DCT cells? It has been known for a long time that the entire distal nephron, and DCT cells in particular, expresses luminal P2Y2 receptors, which trigger rapid intracellular  $\text{Ca}^{2+}$  transients when stimulated by purinergic agonists such as adenosine triphosphate (ATP) and



uridine triphosphate (UTP) [20]. These brief  $[Ca^{2+}]_{cyt}$  transients cause a decrease in several transport systems including those involved in NaCl reabsorption [21]. Studies in a mouse DCT (mDCT) cell line showed that PV modulates the shape and duration of intracellular  $Ca^{2+}$  transients induced by ATP [12]. In turn, these changes were reflected by major modifications in the expression of endogenous NCC expression in these cells. The fact that PV is capable of effectively reducing the amplitude of ATP-evoked elevations in  $[Ca]_{cyt}$  in mDCT cells [12] could be potentially linked to the regulation of NCC expression. Taken together, these studies conducted in *Pvalb* KO mice and in mDCT cells suggest that PV could regulate the expression of NCC by modulating intracellular  $Ca^{2+}$  signalling in response to extracellular ATP in DCT cells.

### Potential roles of PV in $Ca^{2+}$ and $Mg^{2+}$ handling by the kidney

Considering the buffering properties of PV, one may hypothesize that this protein could play a direct role in the transepithelial handling of  $Ca^{2+}$  and  $Mg^{2+}$  in the distal nephron. The major sites for transcellular  $Ca^{2+}$  reabsorption in mouse kidney are the late DCT and the CNT [11]. The early part of the DCT appears to play a minor role in  $Ca^{2+}$  transport as apical TRPV5 and basolateral NCX and PMCA are either not detected or only weakly expressed in this segment (Figures 1 and 2). The exclusive distribution of PV in the early DCT and the fact that its expression is independent of the vitamin D3 status also argues against a major role in distal calcium handling [13, 18]. Nevertheless, *Pvalb* KO mice show an increased bone mineral density and a strongly positive calcium balance when stimulated by thiazide diuretics [12]. In fact, such a phenotype is consistent with a reduced NCC expression in the DCT, similar to chronic thiazide administration. Volume contraction in the *Pvalb* KO mice is probably an important factor to explain the positive calcium balance, as indicated by decreased lithium clearance [12, 19]. Nonetheless, other components of the  $Ca^{2+}$ -signalling toolkit [3] might be modified in *Pvalb* KO mice and a study to address this question is underway (Schwaller, unpublished work).

It must be pointed out that even volume-repleted *Pvalb* KO mice tend to excrete less calcium than their wild-type littermates [12], which could in fact originate from a dysfunctional NCC. Gesek and Friedman [22] demonstrated that a reduced  $Cl^-$  entry in DCT cells leads to decreased intracellular  $Cl^-$  activity followed by hyperpolarization of the plasma membrane. The hyperpolarization was proposed to activate dihydropyridine-sensitive calcium channels in the apical membrane, which enhances transcellular  $Ca^{2+}$  transport [22]. A similar mechanism could operate in DCT cells lacking PV, due to the down-regulation of NCC. However, it is unclear whether a hyperpolarization of the luminal membrane would persist under the chronic conditions of a life-long decrease in NCC activity. Alternatively, a decreased urinary calcium excretion may also

be explained by a decreased intracellular  $Na^+$  concentration, resulting from a decreased apical NCC activity. In this scenario, basolateral NCX1 responds by facilitating  $Na^+$  entry into the cell and  $Ca^{2+}$  exit out of the cell, enhancing the net transcellular  $Ca^{2+}$  flux [23]. A third mechanism could be related to a structural hypertrophy of the TRPV5 and NCX/PMCA1b-positive CNT, as observed in NCC-deficient mice [24], which would increase the epithelial surface available for transcellular  $Ca^{2+}$  reabsorption. Nevertheless, careful histological examinations have not detected such damages in the kidneys of the *Pvalb* KO mice. Similarly, no compensatory up-regulation of TRPV5 or calbindin- $D_{28k}$ , as observed after chronic administrations of thiazide diuretics [25], has been observed in the *Pvalb* KO kidneys.

Elegant studies have shown that calbindin- $D_{28k}$ , which is expressed in DCT2, may make use its  $Ca^{2+}$ -sensing properties to function differently at basal  $[Ca^{2+}]_{cyt}$  and at elevated levels caused by a  $Ca^{2+}$  influx. Accordingly, elevated  $[Ca^{2+}]_{cyt}$  levels could induce conformational changes and regulatory processes including a negative feedback on the apical TRPV5 [17]. Nevertheless, such a mechanism seems unlikely to occur for PV, which is more a 'simple'  $Ca^{2+}$  buffer protein than a  $Ca^{2+}$  sensing and regulatory protein.

PV is distributed, along with TRPM6 and NCC, in the DCT1 segment that plays a crucial role in  $Mg^{2+}$  handling. The affinity of PV for  $Mg^{2+}$  ( $K_{Mg}$ :  $\sim 30 \mu M$ ) makes a suitable candidate to feasibly act as an intracellular  $Mg^{2+}$  transporter/shuttle. For instance, inappropriate urinary loss of  $Mg^{2+}$  is a hallmark of Gitelman syndrome (GS), an inherited tubulopathy due to loss-of-function mutations in NCC (see below). Intracellular  $Mg^{2+}$  (and also  $Ca^{2+}$ ) concentrations tightly regulate their own reuptake through a negative feedback involving apical transporters (TRPM6, TRPV5). Changes in  $[Mg^{2+}]_{cyt}$  have been shown to modify regulatory elements in non-coding mRNA regions, also influencing the transcription of  $Mg^{2+}$  transporters in bacteria [26]. Accordingly, a loss of PV could induce such a negative feedback (decreased apical TRPM6), which would decrease the gradient for passive cellular  $Mg^{2+}$  entry and impair  $Mg^{2+}$  diffusional flux [17, 27]. A mild  $Mg^{2+}$  wasting phenotype has been observed in *Pvalb* KO mice on a C57BL/6J background (Olinger, unpublished work), but further investigations have to be done to confirm these findings.

It is important to mention that there are significant differences between *Slc12a3* KO mice lacking NCC and those lacking PV. Most importantly, NCC-null mice show a more substantial and constant  $Mg^{2+}$  loss in urine and hypomagnesaemia at baseline, probably consistent with severe DCT damage/loss and a loss of TRPM6-expressing cells in the distal nephron. The morphological alterations in DCT seem to be limited to its early part and are most likely a result from reduced transcellular  $Na^+$  transport, raising the question why these ultrastructural changes were not observed in the *Pvalb* KO mice [12, 24]. Perhaps, the reduction in NCC activity and hence transcellular  $Na^+$  transport in the DCTs of PV-deficient mice is not severe enough to provoke the structural changes as they occur in mice lacking any NCC activity. Experiments

addressing this issue are underway in the laboratory of Loffing.

### ***PVALB* as candidate gene in Gitelman syndrome**

The combination of mild sodium wasting, resistance to thiazide diuretics, hypocalciuria and increased bone density observed in *Pvalb* KO mice is reminiscent of the manifestations of GS. GS is a recessively inherited salt-losing tubulopathy with hypokalemic alkalosis, hypomagnesaemia and hypocalciuria. The majority of patients with GS are compound heterozygous for loss-of-function mutations in the *SLC12A3* gene that codes for the NCC [28]. A few cases are caused by mutations in the *CLCNKB* gene that codes for the basolateral ClC-Kb chloride channel in DCT cells [28, 29]. GS is probably the most common tubulopathy, with a prevalence of heterozygous carrier of an *SLC12A3* mutation estimated at 1% in European populations [30]. Most patients with GS are diagnosed in adulthood and are typically normotensive, with a mild phenotype. Recent studies have pointed to the possibility of severe complications, sometimes involving children and potentially related to male gender and specific allele combinations [31].

Despite advances in mutation detection in *SLC12A3*, up to 30% of patients with GS carry only a single mutant allele and negative *SLC12A3* screening is observed in ~10% of patients [29, 31]. Mutations in another gene could thus explain the lack of detection of mutant *SLC12A3* alleles in GS patients. Considering the phenotype of the PV KO mouse, it was tempting to hypothesize that mutations in *PVALB*, the gene coding for PV, could be present in patients with GS heterozygous or in ones negative for *SLC12A3* mutations [32]. The *PVALB* gene, localized on chromosome 22 (22q12-q13.1), has not been linked to any human disorder so far. Direct sequencing of *PVALB* was performed in 132 GS patients harbouring only one ( $n = 53$ ) or no ( $n = 79$ ) mutant *SLC12A3* allele. The possible interference of biallelic SNPs (single nucleotide polymorphisms) on normal transcription or normal splicing was investigated. No sequence variants resulting in amino acid substitution or a truncated protein within the *PVALB* gene were found in the 264 chromosomes tested. Ten biallelic SNPs, including six novel polymorphisms, were identified: five in the 5' UTR, none of them affecting predicted regulatory elements; three in the coding region, without alteration of the consensus splice sites and two in the 3' UTR. The observed allelic frequencies did not differ significantly between GS patients and controls. These results strongly suggest that mutations in the *PVALB* gene are not involved in the classical form of GS [32].


Despite these negative results, it may be of interest to screen for *PVALB* mutations in patients harbouring neurological symptoms, such as epileptic seizures, in particular when these manifestations are linked to hypomagnesaemia. Central manifestations have been described in *Pvalb* KO mice, suggesting that a distinct neurological phenotype could result from the lack of PV (see below). One could also hypothesize that changes in the expression or

function of PV (or in the  $\text{Ca}^{2+}$  signalling pathway in DCT cells) may participate in the individual response to thiazide diuretics [12].

### **PV and renal cell carcinoma**

In more than 90% of cases, renal cell carcinoma (RCC) originates from tubular cells. The accurate typing of RCC has important implications for prognosis and therapy. In a normal clinical setting, the histologic diagnosis of RCC is made by routine light microscopy of haematoxylin–eosin stained sections. However, immunohistochemical analysis based on segmental markers is important for the differential diagnosis of non-renal cell neoplasms mimicking RCC, the differentiation of histological subtypes or rare RCC, the analysis of a small biopsy specimen and most importantly, the recognition of RCC metastases in distant organs. The immunohistochemical diagnosis of RCC is based on a set of markers indicative of the nephron segment of origin. As mentioned before, PV is exclusively expressed in the first part of the DCT in human kidney [12]. Reactivity for PV is therefore used, along with cadherin, claudins and S100A, as a highly specific and reliable marker of chromophobe RCC and benign oncocytoma, two neoplasms deriving from the distal nephron (Figure 3). In contrast, PV is not expressed in other renal neoplasms and especially in clear cell and papillary RCC.

Chromophobe carcinoma accounts for 5% of all RCC and is considered to present a rather indolent behaviour with localization restricted to the kidney and nuclear Grade 2 at presentation. It is classically divided into a typical variant and an eosinophilic variant, with a differential diagnosis including clear cell carcinoma, papillary RCC and benign oncocytoma. PV staining is a reliable marker of chromophobe carcinoma, superior to Hale's colloidal iron and antimitochondrial 113-1 antibodies [33]. Immunostaining for other distal  $\text{Ca}^{2+}$ -binding



**Fig. 3.** PV as a marker of chromophobe RCC. Immunohistochemical analysis reveals a strong and ubiquitous expression of PV in a chromophobe renal carcinoma (Inset, illustrating the intense staining in chromophobe cancer cells), and staining of the early DCT of the normal renal parenchyma. (Image courtesy of Dr S. Aydin.)

proteins such as calbindin-D<sub>28k</sub> is most often negative and much less specific than PV for oncocytoma and chromophobe RCC. Staining for PV is of limited value to differentiate the eosinophilic variant of chromophobe RCC from oncocytoma, the most common benign renal neoplasm. The distinction is particularly challenging for so-called hybrid tumours, revealing features of both oncocytoma and chromophobe RCC and reflecting probably the common origin of these two tumours. Nevertheless, a negative or a patchy staining for PV is strongly suggestive towards the diagnosis of oncocytoma [34]. PV is also strongly expressed in the (rare) metastases from chromophobe RCC [33, 35].

Instead of being only a simple marker, could PV be a causative agent in renal tumour development? It is of interest that  $\beta$ -PV (oncomodulin) has been shown to activate cyclic nucleotide phosphodiesterase and can thereby act as a cellular trigger protein [36]. Oncomodulin is frequently expressed in mammalian tumours, for instance in Morris hepatoma [37]. However, PV and oncomodulin differ by their Ca<sup>2+</sup>-binding sites. Oncomodulin has one Ca<sup>2+</sup>-specific, non-canonical site (CD domain) and one mixed (Ca<sup>2+</sup>/Mg<sup>2+</sup>)-binding site (EF domain). The CD domain shows significant Ca<sup>2+</sup>-dependent conformation changes, suggestive of additional sensor function for oncomodulin [2]. An active role of PV in tumour genesis cannot be excluded, but would be likely based on altered intracellular Ca<sup>2+</sup> signalling. Until now, no interacting partner indicative of a Ca<sup>2+</sup> sensor function has been identified.

## PV outside the kidney

PV is highly expressed in a subgroup of inhibitory GABAergic interneurons in various brain regions including cortex, hippocampus, striatum and cerebellum (for more details, see [7]) and in fast-twitch muscle fibres [14]. It has been postulated that the absence of PV in GABAergic interneurons and in particular in chandelier cells and basket cells is correlated with an increased susceptibility to epileptic seizures in *Pvalb* KO mice [10]. The modulation of [Ca<sup>2+</sup>]<sub>cyt</sub> kinetics in neurons lacking PV leads to increased facilitation of GABAergic transmission to postsynaptic pyramidal cells, thus resulting in a shift in the pyramidal cell's firing properties which could, under certain experimental conditions, lead to epileptogenic insults. Indeed, the severity of pentylenetetrazole-induced generalized tonic-clonic seizures is significantly greater in *Pvalb* KO mice compared with wild-type littermates [10]. PV KO mice also display a mild impairment in motor coordination and motor learning [38]. There is evidence that PV plays a similar role in the epileptogenic activity of the human neocortex based on results of PV immunoreactivity in epileptic foci [39].

With respect to fast-contracting muscle activity, the contraction-relaxation cycle is prolonged in *Pvalb* KO muscle fibres, with a significantly greater force generated during a single twitch [9]. These changes result from an altered shape of Ca<sup>2+</sup> transients in the absence of PV.

A possible role of PV as a signal transduction modulator in human parathyroid gland cells by affecting [Ca<sup>2+</sup>]<sub>cyt</sub> is also envisaged, potentially related to the control of PTH secretion [8].

## Conclusion and perspectives

PV is a classical member of the EF-hand protein superfamily that plays a role in regulatory processes operating in very distinct cell types. PV has been described as a Ca<sup>2+</sup> buffer and Ca<sup>2+</sup> transporter/shuttle protein, but diverse experimental observations hint towards an additional role in magnesium handling. It is particularly puzzling that PV is exclusively expressed in the early part of the DCT of the human and mouse kidneys. A role of PV in the renal handling of electrolytes was demonstrated in *Pvalb* KO mice, which showed a mild salt-losing phenotype with salt craving, relatively similar to GS. A link between the Ca<sup>2+</sup>-buffering capacity of PV and the expression of the thiazide-sensitive NCC could be established, with potential relevance for the regulation of sodium transport in the distal nephron. On the basis of these studies, *PVALB* has been proposed as a candidate gene in patients presenting with GS and displaying none or only a single mutant *SLC12A3* allele. However, no link between mutations in *PVALB* and GS could be established so far. Variants in *PVALB* have been described, but their relevance to kidney function or response to thiazide diuretics, for instance, has not been investigated. Finally, PV is considered a reliable marker of chromophobe carcinoma and oncocytoma, two neoplasms deriving from the distal nephron. The putative role of PV in tumour genesis has not yet been investigated. The role of PV in tissues apart from the kidney is best understood in neurons, where its absence affects short-term modulation of synaptic transmission.

**Acknowledgements.** We thank Drs Selda Aydin and Sara Terryn for their contributions. Studies mentioned in this review were supported in part by the Fonds National de la Recherche Scientifique; the Fonds de la Recherche Scientifique Médicale; an Action de Recherche Concertée; an Inter-University Attraction Pole (IUAP); the NCCR Kidney.CH program and the Swiss National Science Foundation: grant # 130680 (to B.S.).

**Conflict of interest statement.** None declared.

## References

1. Kretsinger RH, Nockolds CE. Carp muscle calcium-binding protein. II. Structure determination and general description. *J Biol Chem* 1973; 248: 3313–3326
2. Schwaller B. Cytosolic Ca<sup>2+</sup> buffers. *Cold Spring Harb Perspect Biol* 2010; 2: a004051
3. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* 2003; 4: 517–529
4. Gifford JL, Walsh MP, Vogel HJ. Structures and metal-ion-binding properties of the Ca<sup>2+</sup>-binding helix-loop-helix EF-hand motifs. *Biochem J* 2007; 405: 199–221
5. Grabarek Z. Structural basis for diversity of the EF-hand calcium-binding proteins. *J Mol Biol* 2006; 359: 509–525
6. Ikura M. Calcium binding and conformational response in EF-hand proteins. *Trends Biochem Sci* 1996; 21: 14–17



7. Celio MR. Calbindin D-28k and parvalbumin in the rat nervous system. *Neuroscience* 1990; 35: 375–475
8. Pauls TL, Portis F, Macri E *et al.* Parvalbumin is expressed in normal and pathological human parathyroid glands. *J Histochem Cytochem* 2000; 48: 105–111
9. Schwaller B, Dick J, Dhoot G *et al.* Prolonged contraction-relaxation cycle of fast-twitch muscles in parvalbumin knockout mice. *Am J Physiol Cell Physiol* 1999; 276: C395–C403
10. Schwaller B, Tetko IV, Tandon P *et al.* Parvalbumin deficiency affects network properties resulting in increased susceptibility to epileptic seizures. *Mol Cell Neurosci* 2004; 25: 650–663
11. Loffing J, Loffing-Cueni D, Valderrabano V *et al.* Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron. *Am J Physiol Renal Physiol* 2001; 281: F1021–F1027
12. Belge H, Gailly P, Schwaller B *et al.* Renal expression of parvalbumin is critical for NaCl handling and response to diuretics. *Proc Natl Acad Sci USA* 2007; 104: 14849–14854
13. Bindels RJM, Timmermans JAH, Hartog A *et al.* Calbindin-D9k and parvalbumin are exclusively located along basolateral membranes in rat distal nephron. *J Am Soc Nephrol* 1991; 2: 1122–1129
14. Celio MR, Heizmann CW. Calcium-binding protein parvalbumin is associated with fast contracting muscle fibres. *Nature* 1982; 297: 504–506
15. Reilly RF, Ellison DH. Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. *Physiol Rev* 2000; 80: 277–306
16. Hoenderop JGJ, Nilius B, Bindels RJM. Calcium absorption across epithelia. *Physiol Rev* 2005; 85: 373–422
17. Hoenderop JGJ, Bindels RJM. Calcitropic and magnesiotropic TRP channels. *Physiology* 2008; 23: 32–40
18. Koster HP, Hartog A, Van Os CH *et al.* Calbindin-D28K facilitates cytosolic calcium diffusion without interfering with calcium signaling. *Cell Calcium* 1995; 3: 187–196
19. Nijenhuis T, Vallon V, van der Kemp AWC *et al.* Enhanced passive  $\text{Ca}^{2+}$  reabsorption and reduced  $\text{Mg}^{2+}$  channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. *J Clin Invest* 2005; 115: 1651–1658
20. Bidet M, De Renzis G, Martial S *et al.* Extracellular ATP increases  $[\text{Ca}^{2+}]_i$  in distal tubule cells. I. Evidence for a P2Y2 purinoceptor. *Am J Physiol Renal Physiol* 2000; 279: F92–F101
21. Leipziger J. Control of epithelial transport via luminal P2 receptors. *Am J Physiol Renal Physiol* 2003; 84: F419–F432
22. Gesek FA, Friedman PA. Mechanism of calcium transport stimulated by chlorothiazide in mouse distal convoluted tubule cells. *J Clin Invest* 1992; 90: 429–438
23. Costanzo LS, Windhager EE. Transport functions of the distal convoluted tubule. In: Andreoli TE, Hoffman JF, Fanestil DD, Schultz SG (eds). *Physiology of Membrane Disorders*. New York, USA: Plenum Medical Book Company, 1986, pp. 727–750
24. Loffing J, Vallon V, Loffing-Cueni D *et al.* Altered renal distal tubule structure and renal  $\text{Na}^+$  and  $\text{Ca}^{2+}$  handling in a mouse model for Gitelman's syndrome. *J Am Soc Nephrol* 2004; 15: 2276–2288
25. Chien-Te L, Shuhua S, Li-Wen L *et al.* Effect of thiazide on renal gene expression of apical calcium channels and calbindins. *Am J Physiol Renal Physiol* 2004; 287: F1164–F1170
26. Cromie MJ, Shi Y, Latifi T *et al.* An RNA sensor for intracellular  $\text{Mg}^{2+}$ . *Cell* 2006; 125: 71–84
27. Hoenderop JGJ, Vennekens R, Müller D *et al.* Function and expression of the epithelial  $\text{Ca}^{2+}$  channel family: comparison of mammalian ECaC1 and 2. *J Physiol* 2001; 537: 747–761
28. Knoers NV, Devuyst O, Kamsteeg EJ. Clinical utility gene card for: Gitelman syndrome. *Eur J Hum Genet* 2011; 19. doi: 10.1038/ejhg.2011.14
29. Vargas-Poussou R, Dahan K, Kahila D *et al.* Spectrum of mutations in Gitelman syndrome. *J Am Soc Nephrol* 2011; 22: 693–703
30. Devuyst O. Salt wasting and blood pressure. *Nat Genet* 2008; 40: 495–496
31. Riveira-Munoz E, Chang Q, Godefroid N *et al.* Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. *J Am Soc Nephrol* 2007; 18: 1271–1283
32. Riveira-Munoz E, Devuyst O, Belge H *et al.* Evaluating PVALB as a candidate gene for SLC12A3-negative cases of Gitelman's syndrome. *Nephrol Dial Transplant* 2008; 23: 3120–3125
33. Martignoni G, Pea M, Chilosi M *et al.* Parvalbumin is constantly expressed in chromophobe renal carcinoma. *Mod Pathol* 2001; 14: 760–767
34. Adley BP, Papavero V, Sugimura J *et al.* Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. *Anal Quant Cytol Histol* 2006; 28: 228–236
35. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. *Arch Pathol Lab Med* 2011; 135: 92–109
36. Mutus B, Karupiah N, Sharma RK *et al.* The differential stimulation of brain and heart cyclic-AMP phosphodiesterase by oncomodulin. *Biochem Biophys Res Commun* 1985; 131: 500–506
37. MacManus JP, Watson DC, Yaguchi M. The complete amino acid sequence of oncomodulin—a parvalbumin-like calcium-binding protein from Morris hepatoma. *Eur J Biochem* 1983; 136: 9–17
38. Farré-Castany MA, Schwaller B, Gregory P *et al.* Differences in locomotor behavior revealed in mice deficient for the calcium-binding proteins parvalbumin, calbindin D-28k or both. *Behav Brain Res* 2007; 178: 250–261
39. DeFelipe J, Garcia Sola R, Marco P *et al.* Selective changes in the microorganization of the human epileptogenic neocortex revealed by Parvalbumin immunoreactivity. *Cereb Cortex* 1993; 3: 39–48

Received for publication: 25.8.2012; Accepted in revised form: 26.8.2012